WHX WORLD HEALTH EXPO

Dubai · 25-28 January

In partnership with

FROST & SULLIVAN

Longevity is redefining healthcare:

From reactive care to lifelong health

October 2026



Table of content

Understanding the longevity imperative	**03**
Redefining healthcare success: Healthspan versus lifespan	03
The science of ageing	04
Building the foundations of longevity	05
The longevity industry's future and the middle east's strategic role	07
Capturing the longevity opportunity	10
The next phase of healthcare transformation	12
Conclusion	**13**

Longevity is redefining healthcare:
From reactive care to lifelong health

WHX WORLD HEALTH EXPO

Understanding the longevity imperative

For decades, healthcare has largely focused on managing symptoms and treating patients after illness occurs. The primary goal was to improve life expectancy, with less emphasis on preventing disease through healthy habits and lifestyle changes. As a result, extending life often took precedence over optimising health.


A profound shift is underway. The longevity imperative is transforming healthcare from a reactive, treatment-focused model into a proactive, prevention-oriented approach. This change is accelerating innovation in preventive care, personalised medicine, health technologies, and lifestyle interventions, with healthcare increasingly focused on extending both lifespan and healthspan.

Redefining healthcare success: Healthspan versus lifespan

Success in healthcare will no longer be measured solely by increases in life expectancy, but by improvements in healthspan: the number of years individuals live in good physical, mental, and social health. As chronic diseases increasingly emerge among people in their 30s and 40s, healthcare systems face growing economic and societal pressures to prioritise prevention and healthy ageing.

The objective is no longer simply to add years to life, but to add life to those years by extending the period during which individuals remain healthy, active, independent, and engaged in society.

Healthspan emphasises maintaining vitality, resilience, cognitive function, mobility, and independence for as long as possible. It encourages a proactive approach to health through lifestyle interventions, preventive screening, personalised medicine, fitness, nutrition, mental well-being, and continuous monitoring of key health indicators.



The science of ageing

For centuries, healthcare has been built around the fundamental objective of diagnosing and treating disease. From traditional medical practices to today's sophisticated diagnostics, significant investments have supported the research and development of technologies that detect cancer, heart disease, diabetes, and many other conditions at increasingly early stages. Advances in blood-based diagnostics, medical imaging, and molecular and genetic testing have focused on identifying disease risk and diagnosing complex conditions before symptoms become severe. Although healthcare has become increasingly effective at detecting disease, it remains less adept at measuring the biological factors that underpin health, resilience, and vitality long before clinical symptoms appear.

The emerging science of longevity is beginning to shift the conversation from **"What disease does a person have?"** to **"How well is a person ageing?"** Advances in longevity research are enabling biological age to be measured through biomarkers including inflammation levels, mitochondrial function, epigenetic clocks, telomere dynamics, muscle strength, metabolic health, and cardiovascular fitness. These indicators can reveal subtle declines in physiological resilience years before a disease is formally diagnosed, creating opportunities for earlier and more targeted interventions. By combining traditional diagnostics with healthspan-focused biomarkers, healthcare can evolve from a reactive disease management model to a proactive model focused on preserving vitality, independence, cognitive function, and quality of life.

As a result, longevity science is attracting growing attention and investment from a diverse range of stakeholders. Leading genomics and diagnostics companies such as Illumina, PacBio, and Oxford Nanopore are advancing technologies that enable biological age measurement and epigenetic analysis. Pharmaceutical leaders including Novo Nordisk and Eli Lilly are driving innovations in metabolic health and chronic disease prevention, while technology companies such as Alphabet, through initiatives like Calico, are investing in the biology of ageing and age-related diseases. At the same time, emerging biotechnology firms such as Insilico Medicine, BioAge Labs, Altos Labs, and other longevity-focused start-ups are exploring new approaches to age-related therapeutics, biomarker discovery, and cellular rejuvenation. Together, these investments are accelerating the transition from a healthcare system focused on disease management to one focused on extending healthspan and enabling healthier ageing.

Building the foundations of longevity

The longevity market can be broadly divided into two interconnected segments: diagnostics and therapeutics. Although diagnostics play a critical role in identifying biological ageing, disease risk, and declining health resilience, the longevity ecosystem cannot be sustained by diagnostics alone. The true value of longevity medicine lies in translating diagnostic insights into interventions that improve health outcomes and extend health span. Unlike traditional healthcare, longevity therapeutics extend far beyond pharmaceuticals and surgery and include lifestyle interventions, nutrition, exercise, sleep optimisation, behavioural modifications, digital therapeutics, and preventive health programmes.

As a result, longevity is emerging as a highly integrated ecosystem that brings together diagnostics companies, biotechnology and pharmaceutical firms, medical device manufacturers, digital health providers, artificial intelligence platforms, healthcare service organisations, and wellness innovators. Collectively, these stakeholders are shaping a rapidly growing multibillion-dollar industry focused on extending healthy and productive years of life rather than simply treating disease.

To realise the full potential of longevity medicine, five foundational building blocks must be established:

› Robust biomarker infrastructure

The first pillar is the development of a robust biomarker infrastructure capable of measuring biological age and health vitality with a high degree of accuracy. Key biomarkers include inflammation markers, muscle strength, cardiovascular fitness (VO max), mitochondrial function indicators, metabolic health measures, and genomic and epigenomic markers. Together, these indicators provide a more comprehensive picture of an individual›s health trajectory than traditional disease-based diagnostic measures. The ability to monitor these biomarkers continuously will be fundamental to identifying health risks early and enabling timely interventions.

› Clinical validation and scientific evidence

Clinical validation represents the second critical building block. For longevity medicine to move beyond the wellness sector and achieve mainstream adoption, biomarkers and interventions must be supported by rigorous scientific evidence and regulatory acceptance. Establishing validated links between biomarkers and long-term health outcomes will be essential for gaining the confidence of clinicians, payers, regulators, and patients. Furthermore, the acceptance of longevity biomarkers as surrogate endpoints in clinical trials has the potential to significantly reduce development timelines, accelerate innovation, and attract greater investment into the sector.

Integrated longevity platforms

The third pillar is the development of integrated longevity platforms. The future of longevity medicine will depend on integrating multiple layers of health data within a unified ecosystem. Combining genomics, epigenomics, proteomics, metabolomics, wearable device data, electronic health records, lifestyle data, and environmental factors through advanced analytics and artificial intelligence can generate deeper insights into the ageing process. Such integrated platforms can detect subtle declines in health resilience and identify ageing signatures years before clinical symptoms appear, enabling truly predictive and personalised healthcare.

Enabling policy frameworks

Government-led policy frameworks will play a decisive role in shaping the longevity economy. Most healthcare regulatory systems were designed around disease diagnosis and treatment rather than prevention and healthy ageing. As policymakers begin to recognise the value of prevention, there is an opportunity to establish regulatory pathways that support biological age testing, longevity diagnostics, preventive interventions, and healthspan-focused clinical research. Regulatory innovation can reduce investment risk, encourage private-sector participation, and accelerate the commercialisation of longevity solutions.

Incentives for adoption and growth

The final pillar is incentives. Both industry participants and the broader population require clear reasons to adopt and invest in longevity-focused healthcare. One of the most significant opportunities lies in aligning healthcare reimbursement models with prevention rather than treatment. Healthcare systems could include coverage for biological age assessments, incentives for fitness and wellness programmes, premium discounts linked to preventive health metrics, and reimbursement for clinically validated longevity interventions. These mechanisms would encourage proactive health management, drive large-scale adoption, and create a sustainable economic foundation for the longevity industry.

The success of the longevity ecosystem will depend on the coordinated development of these five pillars to support the transformation of the healthcare industry from disease management to a model centred on preserving health, vitality, independence, and quality of life throughout the lifespan.



The longevity industry's future and the middle east's strategic role

As the longevity industry evolves from a niche scientific field into a mainstream healthcare priority, several countries and organisations have emerged as global leaders by creating supportive ecosystems for research, innovation, regulation, investment, and clinical adoption. The most successful longevity hubs share common characteristics: strong public-private collaboration, access to capital, progressive regulation, advanced healthcare infrastructure, and robust data ecosystems.

United States: Research excellence and capital development

The United States remains the global leader in the longevity industry owing to its concentration of world-class universities, research institutions, biotechnology companies, healthcare innovators, and venture capital networks. Organisations such as Calico, Altos Labs, BioAge Labs, and numerous academic research centres are advancing breakthroughs in ageing biology, epigenetic reprogramming, biomarkers, regenerative medicine, and longevity therapeutics. The United States has successfully combined scientific excellence with deep pools of private capital and a strong entrepreneurial culture, enabling the rapid translation of scientific discoveries into commercially viable products and therapies.

Singapore: Regulatory innovation and data ecosystem development

Singapore has established itself as one of the world's leading centres for precision medicine, preventive healthcare, and biomedical innovation through sustained government investment. The country has successfully integrated healthcare delivery, genomics, digital health, and population health programmes through nationally coordinated initiatives focused on personalised medicine and healthy ageing. Singapore's strong regulatory framework, government-led innovation agenda, and advanced digital infrastructure have enabled the development of a highly coordinated longevity ecosystem that supports both research and implementation.



Switzerland: Clinical infrastructure and translational research

Switzerland has leveraged its global pharmaceutical leadership, research institutions, and healthcare infrastructure to become one of the world's foremost life sciences hubs. Its strength lies not only in scientific discovery but also in translating research into clinical applications through close collaboration between universities, hospitals, biotechnology companies, and pharmaceutical organisations. Switzerland's integrated approach has created an environment where scientific innovations can be effectively validated and adopted within clinical practice.

United Kingdom: Data and technology ecosystem development

The United Kingdom has become a global leader in health data, genomics, and population health research. Through extensive longitudinal health studies, national healthcare datasets, and advanced genomics initiatives, the UK has created one of the world's richest resources for understanding ageing, disease progression, and health outcomes. The integration of healthcare data, research institutions, and genomics programmes provides a powerful platform for advancing precision medicine and longevity science.

Among these emerging centres, the UAE is positioning itself as a regional hub for longevity and preventive health innovation. The country has successfully attracted international healthcare providers, industry, researchers, and investors through its world-class healthcare infrastructure, business-friendly environment, advanced digital capabilities, and strong commitment to innovation. These strengths provide a solid foundation for the commercialisation of longevity solutions. The UAE's strategic location also enables it to serve as a bridge connecting innovation ecosystems across Europe, Asia, and Africa.



The Middle East's greatest opportunity lies in its ability to establish itself as a leading global longevity hub by 2035–2040. Rather than attempting to replicate existing scientific clusters, the region should focus on areas where it possesses clear competitive advantages. The key priorities should be:

- Capital development: With access to sovereign wealth funds, family offices, institutional investors, and international capital markets, the UAE has the potential to become the world's leading financier of longevity innovation. By creating dedicated longevity investment funds, venture platforms, startup accelerators, and global investment forums, the region can attract researchers, entrepreneurs, and companies developing the next generation of longevity technologies. This represents the fastest path to establishing global relevance within the longevity sector.

- Regulatory innovation: One of the biggest bottlenecks facing the global longevity industry is the lack of regulatory frameworks designed around prevention and healthy ageing. The UAE has an opportunity to become the world's most innovation-friendly jurisdiction for longevity technologies by introducing longevity regulatory sandboxes, fast-track approval pathways for diagnostics and digital health solutions, accelerated validation frameworks for biomarkers, regulatory guidance for biological age testing, and reimbursement models that encourage preventive healthcare. Such initiatives would attract global companies seeking a faster and more supportive route to commercialisation while maintaining rigorous standards for safety and efficacy.

- Clinical infrastructure development: The UAE can establish itself as a premier destination for longevity medicine by building exemplar longevity clinics, precision medicine institutes, biomarker testing centres, preventive health facilities, and regenerative medicine centres. These institutions can serve as platforms for delivering personalised healthcare while also supporting clinical research, innovation, and medical tourism. By integrating genomics, biomarker monitoring, lifestyle interventions, and advanced diagnostics into routine care, Dubai can create a differentiated healthcare offering centred on extending healthspan rather than simply treating disease.

By pursuing this strategy, the Middle East has a unique opportunity to become a globally recognised centre for longevity medicine, helping drive the transition from reactive healthcare to proactive healthspan management while generating significant economic, societal, and healthcare benefits.

Capturing the longevity opportunity

As longevity medicine evolves from a niche scientific field into a mainstream healthcare sector, three growth opportunities are emerging as the most significant drivers of future value creation.

Longevity diagnostics and biomarker testing

The first major growth opportunity lies in longevity diagnostics and biomarker testing. Establishing biological age and healthspan measurement as routine components of healthcare, much like annual health screenings today, has the potential to transform preventive medicine. As healthcare systems shift their focus from disease detection to measuring health, resilience, and ageing trajectories, biological age testing, epigenetic analysis, multi-omics diagnostics, and healthspan monitoring are expected to become mainstream components of care. Industry estimates suggest that the global longevity diagnostics market could be a multibillion-dollar opportunity by 2035, driven by advances in biomarker science, increasing consumer demand for preventive healthcare, and the expanding adoption of precision medicine.

Longevity therapeutics and preventive interventions

The second major growth opportunity lies in longevity therapeutics and preventive interventions designed to slow, prevent, or reverse age-related decline. These interventions span a broad spectrum, including regenerative medicine, cellular reprogramming, senolytics, metabolic therapies, precision nutrition, lifestyle interventions, digital therapeutics, and next-generation pharmaceuticals. Leading organisations such as Altos Labs, Calico, BioAge Labs, Life Biosciences, and other biotechnology innovators are investing heavily in understanding the biological pathways associated with ageing, including cellular senescence, mitochondrial dysfunction, epigenetic changes, inflammation, and metabolic decline. The broader longevity biotechnology and therapeutics ecosystem is projected to be a multibillion-dollar market by 2035 and aid in the transition towards healthspan-focused medicine.

Integrated longevity platforms

The largest long-term opportunity may be the creation of integrated longevity platforms that bring together diagnostics, therapeutics, genomics, digital health, wearable technologies, artificial intelligence, and clinical care within a single ecosystem. The long-term vision is the creation of a “health operating system” that manages healthspan in the same way financial platforms manage wealth over a lifetime. Such platforms would enable continuous assessment of health resilience, early detection of physiological decline, personalised prevention strategies, and real-time optimisation of wellness across physical, metabolic, cognitive, and behavioural dimensions. The convergence of multi-omics data, wearable technologies, artificial intelligence, telehealth, and preventive medicine is expected to fundamentally transform healthcare delivery from a reactive model to a proactive and predictive one.

As investments in precision health, AI-powered healthcare, digital therapeutics, and longevity services continue to accelerate, integrated longevity platforms are expected to evolve into a multibillion-dollar market by 2035, representing one of the largest segments of the broader longevity economy.



The next phase of healthcare transformation

Longevity is no longer a future healthcare concept but an emerging strategic imperative that is reshaping healthcare systems, business models, and investment priorities worldwide. Organizations that act today to build capabilities in healthspan measurement, predictive analytics, preventive care, precision medicine, and integrated care delivery will be best positioned to lead the next wave of healthcare transformation and capture value within the evolving longevity economy.

Frost & Sullivan's analysis indicates that the evolving health needs of governments, employers, payers, and healthcare providers will accelerate the transition toward outcome-based healthcare models that reward prevention, resilience, functional independence, and healthy ageing rather than treatment volumes alone.

Looking ahead, it envisions the emergence of global longevity platforms that seamlessly integrate diagnostics, digital health, predictive analytics, preventive interventions, clinical services, and consumer engagement into unified health management ecosystems. While early versions of these platforms are expected to become a commercial reality during this decade, broader adoption and scalable implementation are likely to accelerate in the following decade. These platforms will function as lifelong health companions, continuously monitoring individual health trajectories and enabling the proactive optimization of physical, cognitive, metabolic, and emotional well-being. In doing so, they will help redefine healthcare delivery from episodic treatment of illness to continuous management of healthspan across an individual's lifetime.



Conclusion

The transition from reactive care to longevity-focused healthcare represents one of medicine's most significant transformations. Longevity is about more than extending life expectancy; it is about giving equal, if not greater, emphasis to preserving health, preventing disease, and optimising physical, mental, and social well-being throughout life.

The longevity economy is emerging as a significant frontier for innovation, investment, and healthcare transformation. By bringing together diagnostics, therapeutics, digital health, medical technologies, and preventive care solutions, the sector has the potential to reshape healthcare delivery, improve population health outcomes, and reduce the long-term burden of chronic disease. As scientific understanding of ageing advances, healthcare systems will increasingly move from managing illness to maintaining vitality, resilience, and independence.

For the Middle East, and particularly the UAE, this transformation presents a unique strategic opportunity. By leveraging its strengths in capital deployment, regulatory agility, world-class healthcare infrastructure, and innovation-driven economic development, the region is well positioned to establish itself as a leading global hub for longevity medicine and healthy ageing. Strategic investments in funding, regulation, clinical infrastructure, and innovation ecosystems can accelerate the commercialisation and adoption of next-generation longevity solutions.

As governments, healthcare systems, investors, and industry leaders enable the convergence of diagnostics, therapeutics, artificial intelligence, digital health, and precision medicine, longevity is emerging as one of the most important innovation frontiers of the 21st century. Countries and organisations that act today will not only help redefine healthcare but also shape a future in which adding life to years is as important as adding years to life.


Sources:
Frost & Sullivan Analysis
AARP International – Longevity Economy Outlook
Longevity Technology Insights
Bank of America article on 2026 Supertrends: The Longevity Economy

WHX WORLD HEALTH EXPO
Dubai · 25-28 January

WHX Tech
Dubai · 26-28 January

WHX Leaders
Dubai · 26 January

In partnership with
FROST & SULLIVAN



Where the world of healthcare meets

25-28 January 2027
Dubai Exhibition Centre,
Expo City
Dubai World Trade Centre

Buy your ticket